AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
Rhea-AI Summary
AirSculpt Technologies (NASDAQ:AIRS) reported fourth-quarter and full-year fiscal 2025 results, with revenue of $33.4M in Q4 and $151.8M for full-year 2025. Case volume declined ~15% year-over-year to 2,604 in Q4 and 11,852 for 2025. Full-year adjusted EBITDA was $15.1M and net loss was $11.7M. The company issued 2026 guidance of $151–$157M revenue and $15–$17M adjusted EBITDA. As of Dec 31, 2025 cash was $8.4M, gross debt ~$56M, with subsequent ATM proceeds of $14.8M and debt reduced to ~$45M.
AirSculpt set its annual meeting for May 12, 2026 and will host a conference call on April 2, 2026.
AI-generated analysis. Not financial advice.
Positive
- Adjusted EBITDA improved to $2.5M in Q4 versus $1.9M
- Raised $14.8M via ATM in 2026 first quarter
- Reduced gross debt to approximately $45M after $11.0M paydown
- Issued 2026 guidance of $151–$157M revenue, signaling stabilization
Negative
- Full-year revenue declined 15.8% to $151.8M
- Case volume fell 15.6% year-over-year to 11,852
- Full-year adjusted EBITDA declined 28% to $15.1M
- Net loss widened to $11.7M for full-year 2025
News Market Reaction – AIRS
On the day this news was published, AIRS gained 16.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.6% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $31M to the company's valuation, bringing the market cap to $224.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, AIRS was down 3.53% while key peers showed small mixed moves (EHAB and CCRN down modestly, CYH, AUNA, NUTX up). No peers appeared in the momentum scanner, suggesting a stock-specific setup rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings date notice | Neutral | -3.5% | Set timing for Q4 and full-year 2025 earnings call and webcast. |
| Mar 16 | Filing delay update | Negative | +44.6% | Announced NT 10-K and preliminary 2025 figures plus Q1 2026 revenue view. |
| Nov 17 | Leadership change | Positive | -2.4% | Appointed experienced healthcare executive Mike Doyle as non-executive chairman. |
| Nov 07 | Q3 2025 earnings | Negative | -41.7% | Reported revenue and case declines with reduced 2025 guidance and highlighted leverage. |
| Oct 31 | Earnings date notice | Neutral | -1.6% | Announced schedule and access details for Q3 2025 earnings call. |
Historical reactions skew negative on weak fundamentals, with large downside on poor Q3 results and modest declines around routine announcements, but one notable upside divergence on the filing-delay and business update.
Over the last six months, AIRS news has centered on earnings cadence, a major Q3 2025 reset, and governance changes. The November 7, 2025 Q3 results, featuring revenue and case volume declines plus lowered guidance, saw a sharp -41.66% move. A November 17, 2025 chairman appointment was followed by a mild decline. In March 2026, the company pre-announced 2025 results and an NT 10-K, yet shares rose 44.59%. Today’s full-year 2025 release formalizes those preliminaries, tying back to that earlier update and the recent 10-K filing on March 31, 2026.
Market Pulse Summary
The stock surged +16.1% in the session following this news. A strong positive reaction aligns with investors emphasizing improving Q4 profitability metrics despite full-year declines. Sequential gains in same-store trends and higher Q4 Adjusted EBITDA of $2.5 million versus $1.9 million a year earlier, plus 2026 guidance near 2025 revenue and EBITDA levels, could justify enthusiasm. However, the stock entered this report well below its $4.89 200-day MA and off its $12 52-week high, so prior downside, leverage levels and execution on the new go-to-market strategy remained key watchpoints for sustainability.
Key Terms
adjusted ebitda financial
at-the-market offering program financial
revolving credit facility financial
AI-generated analysis. Not financial advice.
MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025.
Yogi Jashnani, Chief Executive Officer, stated: “In the fourth quarter, we delivered sequential improvement in same store sales versus the first nine months of the year and adjusted EBITDA ahead of the prior year period,” stated Yogi Jashnani, Chief Executive Officer. “During 2025, we took significant steps to enhance our business approach and team. We added talent, improved business processes, implemented a new go-to-market strategy, and added new procedures that expanded our market potential."
"The results of this work are already evident,” continued Mr Jashnani. “We entered fiscal 2026 with same-store sales turning positive in February and enhanced financial flexibility to fuel our growth. I'm pleased with our team's unwavering commitment and excited about what lies ahead. AirSculpt is scaled, trusted and strongly positioned at the intersection of aesthetics and GLP-1’s. I'm confident our strategy positions us to create meaningful value for our shareholders," concluded Mr. Jashnani.
Fourth Quarter 2025 Results
- Case volume was 2,604 for the fourth quarter of 2025, representing a
15.0% decline from the fiscal year 2024 fourth quarter case volume of 3,064; - Revenue declined
14.6% to$33.4 million from$39.2 million in the fiscal year 2024 fourth quarter; - Net loss for the quarter was
$1.3 million compared to net loss of$5.0 million in the fiscal year 2024 fourth quarter; and - Adjusted EBITDA was
$2.5 million compared to$1.9 million in the fiscal year 2024 fourth quarter.
Full Year 2025 Results
- Case volume was 11,852, a decline of
15.6% from the full fiscal year 2024 case volume of 14,036; - Revenue declined
15.8% to$151.8 million from$180.4 million in the full fiscal year 2024; - Net loss was
$11.7 million compared to$8.0 million in the full fiscal year 2024; and - Adjusted EBITDA was
$15.1 million compared to$21.0 million in the full fiscal year 2024.
2026 Outlook
The Company projects full year 2026 revenue and adjusted EBITDA guidance as follows:
- Revenue of approximately
$151 t o$157 million - Adjusted EBITDA of approximately
$15 t o$17 million
The Company expects first quarter 2026 revenue of
For additional information on forward-looking statements, see the section titled "Forward-Looking Statements" below.
Debt & Liquidity
As of December 31, 2025, the Company had
Conference Call Information
AirSculpt will hold a conference call today, April 2, 2026 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13758597 or by visiting the link below to request a return call for instant telephone access to the event.
https://callme.viavid.com/viavid/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9MTM3MjUxMTYmaD10cnVlJmluZm89Y29tcGFueSZyPXRydWUmQj02
The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call.
To learn more about AirSculpt, please visit the Company's website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company's website and is readily accessible.
Annual Meeting of Stockholders
The Company noted it changed the date of its Annual Meeting of Stockholders to May 12, 2026. The date of the Annual Meeting of Stockholders was previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as May 4, 2026.
About AirSculpt
AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal U.S. securities laws. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance (including in particular our projected 2026 revenue and adjusted EBITDA), our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K.
Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest.
The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release.
There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time.
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.
Use of Non-GAAP Financial Measures
The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results.
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
| AirSculpt Technologies, Inc. and Subsidiaries Selected Consolidated Financial Data (Dollars in thousands, except shares and per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 33,442 | $ | 39,178 | $ | 151,818 | $ | 180,350 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of service | 13,675 | 16,689 | 61,690 | 71,149 | ||||||||||||
| Selling, general and administrative(1) | 18,216 | 23,355 | 82,180 | 98,880 | ||||||||||||
| Depreciation and amortization | 3,076 | 3,195 | 12,781 | 11,888 | ||||||||||||
| Loss on impairment of long-lived assets(2) | (2,670 | ) | 12 | 4,575 | 16 | |||||||||||
| Cost related to closing location, net(3) | 2,152 | — | 2,152 | — | ||||||||||||
| Total operating expenses | 34,449 | 43,251 | 163,378 | 181,933 | ||||||||||||
| Loss from operations | (1,007 | ) | (4,073 | ) | (11,560 | ) | (1,583 | ) | ||||||||
| Interest expense, net | 1,484 | 1,609 | 6,078 | 6,247 | ||||||||||||
| Pre-tax net loss | (2,491 | ) | (5,682 | ) | (17,638 | ) | (7,830 | ) | ||||||||
| Income tax (benefit)/expense | (3,774 | ) | (706 | ) | (5,971 | ) | 188 | |||||||||
| Net income/(loss) | $ | 1,283 | $ | (4,976 | ) | $ | (11,667 | ) | $ | (8,018 | ) | |||||
| Income/(loss) per share of common stock | ||||||||||||||||
| Basic | $ | 0.02 | $ | (0.09 | ) | $ | (0.19 | ) | $ | (0.14 | ) | |||||
| Diluted | $ | 0.02 | $ | (0.09 | ) | $ | (0.19 | ) | $ | (0.14 | ) | |||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 63,278,594 | 58,121,431 | 60,450,769 | 57,688,906 | ||||||||||||
| Diluted | 68,216,681 | 58,121,431 | 60,450,769 | 57,688,906 | ||||||||||||
| (1) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of |
| (2) | During the fiscal year ended December 31, 2025, the Company recorded a |
| (3) | During the fiscal year ended December 31, 2025, the Company recorded |
| AirSculpt Technologies, Inc. and Subsidiaries Selected Consolidated Financial Data (Dollars in thousands, except shares and per share amounts) | ||||||||
| December 31, 2025 | December 31, 2024 | |||||||
| Balance Sheet Data (at period end): | ||||||||
| Cash and cash equivalents | $ | 8,449 | $ | 8,235 | ||||
| Total current assets | 15,456 | 17,117 | ||||||
| Total assets | $ | 187,304 | $ | 212,781 | ||||
| Current portion of long-term debt | $ | 5,460 | $ | 4,250 | ||||
| Deferred revenue and patient deposits | 1,871 | 1,169 | ||||||
| Total current liabilities | 27,902 | 28,949 | ||||||
| Long-term debt, net | 50,585 | 65,456 | ||||||
| Revolving credit funds payable | — | 5,000 | ||||||
| Total liabilities | $ | 99,592 | $ | 134,593 | ||||
| Total stockholders’ equity | $ | 87,712 | $ | 78,188 | ||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Cash Flow Data: | ||||||||||||||||
| Net cash provided by (used in): | ||||||||||||||||
| Operating activities | $ | (2,531 | ) | $ | 2,713 | $ | 3,096 | $ | 11,350 | |||||||
| Investing activities | (58 | ) | (3,528 | ) | (2,404 | ) | (14,007 | ) | ||||||||
| Financing activities | 5,633 | 3,078 | (478 | ) | 630 | |||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Other Data: | ||||||||||||||||
| Number of facilities | 31 | 32 | 31 | 32 | ||||||||||||
| Number of total procedure rooms | 65 | 67 | 65 | 67 | ||||||||||||
| Cases | 2,604 | 3,064 | 11,852 | 14,036 | ||||||||||||
| Revenue per case | $ | 12,843 | $ | 12,787 | $ | 12,809 | $ | 12,849 | ||||||||
| Adjusted EBITDA(1) | $ | 2,468 | $ | 1,913 | $ | 15,097 | $ | 20,959 | ||||||||
| Adjusted EBITDA margin(2) | ||||||||||||||||
| (1) A reconciliation of this non-GAAP financial measure appears below. |
| (2) Defined as Adjusted EBITDA as a percentage of revenue. |
| AirSculpt Technologies, Inc. and Subsidiaries Selected Consolidated Financial Data (Dollars in thousands, except shares and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Same-center Information(1): | |||||||||||||||
| Cases | 2,345 | 2,879 | 10,670 | 13,689 | |||||||||||
| Case growth | (18.5)% | N/A | (22.1)% | N/A | |||||||||||
| Revenue per case | $ | 12,891 | $ | 12,797 | $ | 12,798 | $ | 12,781 | |||||||
| Revenue per case growth | N/A | N/A | |||||||||||||
| Number of facilities | 31 | 31 | 31 | 31 | |||||||||||
| Number of total procedure rooms | 65 | 65 | 65 | 65 | |||||||||||
| (1) | For the three months ended December 31, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the three months ended December 31, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the three months ended December 31, 2025 in which such facilities were owned and operated during the three months ended December 31, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of December 31, 2024. Beginning September 30, 2025, we have excluded the London facility from all periods presented due to the closure of the facility. |
| For the twelve months ended December 31, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the twelve months ended December 31, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the twelve months ended December 31, 2025 in which such facilities were owned and operated during the twelve months ended December 31, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of December 31, 2024. Beginning September 30, 2025, we have excluded the London facility from all periods presented due to the closure of the facility. |
We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures.
We define Adjusted EBITDA as net income/(loss) excluding depreciation and amortization, net interest expense, income tax (benefit)/expense, restructuring and related severance costs, loss on impairment of long-lived assets, costs related to closing facility and equity-based compensation.
We define Adjusted Net Income as net income/(loss) excluding restructuring and related severance costs, loss on impairment of long-lived assets, cost related to closing facility equity-based compensation and the tax effect of these adjustments.
We include Adjusted EBITDA and Adjusted Net Income because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Income each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Income has limitations as an analytical tool because it does not include results from equity-based compensation.
We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Income per Share as Adjusted Net Income divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Income per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Income per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.
The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net (loss)/income, the most directly comparable GAAP financial measure:
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income/(loss) | $ | 1,283 | $ | (4,976 | ) | $ | (11,667 | ) | $ | (8,018 | ) | ||||
| Plus | | ||||||||||||||
| Equity-based compensation(1) | (1,385 | ) | 2,240 | 2,331 | 3,762 | ||||||||||
| Restructuring and related severance costs | 2,302 | 539 | 4,818 | 6,026 | |||||||||||
| Depreciation and amortization | 3,076 | 3,195 | 12,781 | 11,888 | |||||||||||
| Loss on impairment of long-lived assets(2) | (2,670 | ) | 12 | 4,575 | 16 | ||||||||||
| Cost related to closing location, net(3) | 2,152 | — | 2,152 | — | |||||||||||
| Litigation settlements(4) | — | — | — | 850 | |||||||||||
| Interest expense, net | 1,484 | 1,609 | 6,078 | 6,247 | |||||||||||
| Income tax (benefit)/expense | (3,774 | ) | (706 | ) | (5,971 | ) | 188 | ||||||||
| Adjusted EBITDA | $ | 2,468 | $ | 1,913 | $ | 15,097 | $ | 20,959 | |||||||
| Adjusted EBITDA Margin | 7.4 | % | 4.9 | % | 9.9 | % | 11.6 | % | |||||||
| (1) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of |
| (2) | During the fiscal year ended December 31, 2025, the Company recorded a |
| (3) | During the fiscal year ended December 31, 2025, the Company recorded |
| (4) | This amount relates to settlement costs for non-recurring litigation of |
The following table reconciles Adjusted Net Income and Adjusted Net Income per Share to net income/(loss), the most directly comparable GAAP financial measure:
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income/(loss) | $ | 1,283 | $ | (4,976 | ) | $ | (11,667 | ) | $ | (8,018 | ) | |||||
| Plus | ||||||||||||||||
| Equity-based compensation(1) | (1,385 | ) | 2,240 | 2,331 | 3,762 | |||||||||||
| Restructuring and related severance costs | 2,302 | 539 | 4,818 | 6,026 | ||||||||||||
| Loss on impairment of long-lived assets(2) | (2,670 | ) | 12 | 4,575 | 16 | |||||||||||
Cost related to closing location, net(3) | 2,152 | - | — | 2,152 | — | |||||||||||
Litigation settlements(4) | — | — | — | - | 850 | |||||||||||
| Tax effect of adjustments(5) | (2,771 | ) | (2,267 | ) | (5,621 | ) | (1,271 | ) | ||||||||
| Adjusted net income | $ | (1,089 | ) | $ | (4,452 | ) | $ | (3,412 | ) | $ | 1,365 | |||||
| Adjusted net income (loss) per share of common stock(6) | ||||||||||||||||
| Basic | $ | (0.02 | ) | $ | (0.08 | ) | $ | (0.06 | ) | $ | 0.02 | |||||
| Diluted | $ | (0.02 | ) | $ | (0.08 | ) | $ | (0.06 | ) | $ | 0.02 | |||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 63,278,594 | 58,121,431 | 60,450,769 | 57,688,906 | ||||||||||||
| Diluted | 63,278,594 | 58,876,679 | 60,450,769 | 58,281,133 | ||||||||||||
| (1) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of |
| (2) | During the fiscal year ended December 31, 2025, the Company recorded a |
| (3) | During the fiscal year ended December 31, 2025, the Company recorded |
| (4) | This amount relates to settlement costs for non-recurring litigation of |
| (5) | Within the tax effect of adjustments, any disallowed stock compensation related to 162(m) is used to offset equity-based compensation recognized under GAAP. For the year ended December 31, 2025, there is no disallowed stock compensation related to 162(m) because the prior year awards subject to these limitations have either vested or been forfeited, and no active stock awards are currently subject to these limitations. |
| (6) | Diluted Adjusted Net Income Per Share is computed by dividing adjusted net income by the weighted-average number of shares of common stock outstanding adjusted for the dilutive effect of all potential shares of common stock. |
Investor Contact
Allison Malkin
ICR, Inc.
airsculpt@icrinc.com
